Bramati Annalisa1, Moretti Anna1, Piva Sheila1, Bocci Barbara1, Presazzi Arianna2, Boido Beatrice1, Farina Gabriella1 and Girelli Serena1*
1Department of Oncology, ASST Fatebenefratelli Sacco, Italy 2Department of Radiology, ASST Fatebenefratelli Sacco, ItalyFulltext PDF
In this paper, we report the case of a patient with metastatic renal cell carcinoma who was treated with cabozantinib in a third line setting for 2 weeks and experienced an asymptomatic but severe cardiac impairment, with a decrease of the cardiac Left Ventricular Ejection Fraction (LVEF). This event caused the discontinuation of cabozantinib but surprisingly, despite the short period on treatment, the first disease evaluation performed 3 months later showed a remarkable partial remission of the disease. Moreover, from June 2017 to January 2019 the patient underwent several follow-up CT scans which confirmed the disease response which lasted over 2 years despite never having resumed treatment with cabozantinib.
Annalisa B, Anna M, Sheila P, Barbara B, Arianna P, Beatrice B, et al. A Remarkable Long-Lasting Response to Short Course Cabozantinib Therapy in a Patient with Metastatic Renal Cell Carcinoma. Clin Oncol. 2020; 5: 1747.